February 22, 2017 6:12 PM ET

Biotechnology

Company Overview of DNIB Unwind, Inc.

Company Overview

On October 11, 2016, DNIB Unwind, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. DNIB Unwind, Inc. engaged in the development of novel targeted therapeutics primarily for the treatment of cancer in the United States and Russia. The company was formerly known as BIND Therapeutics, Inc. and changed its name to DNIB Unwind, Inc. in August 2016. DNIB Unwind, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.

325 Vassar Street

Cambridge, MA 02139

United States

Founded in 2006

114 Employees

Phone:

617-491-3400

Key Executives for DNIB Unwind, Inc.

DNIB Unwind, Inc. does not have any Key Executives recorded.

DNIB Unwind, Inc. Key Developments

DNIB Unwind, Inc. Files Form 15

DNIB Unwind, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.0001 per share.

DNIB Unwind, Inc. Deleted From Other OTC

DNIB Unwind, Inc.'s common stock deleted from Other OTC, effective October 11, 2016. The deletion was due to bankruptcy plan effective/shares cancelled.

DNIB Unwind, Inc. To Be Delisted From The Nasdaq Stock Market

On May 2, 2016, DNIB Unwind, Inc. received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) notifying it that its securities would be delisted from Nasdaq due to the Company’s filing on May 1, 2016 for relief under Chapter 11 of the Bankruptcy Code (the “Delisting Determination”). The decision was reached by Nasdaq in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1. The Company appealed the Delisting Determination. On May 10, 2016, the Company received a letter from Nasdaq notifying it that it was no longer in compliance with Nasdaq Listing Rule 5450(b)(1)(A) and does not meet the continued listing requirements under the alternative standards of Listing Rule 5450(b). Also on July 28, 2016, the Company notified Nasdaq of its withdrawal from the appeals process and received a letter from Nasdaq notifying it that its common stock will be delisted, with suspension of trading occurring effective at the open of trading on August 1, 2016. On September 26, 2016, Nasdaq filed a Form 25-NSE with the Securities and Exchange Commission (“SEC”) to complete the delisting and remove the Company’s common stock from registration on The Nasdaq Stock Market. According to the Form 25-NSE, the delisting will become effective at the open of trading on October 6, 2016.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
July 1, 2016
BIND Therapeutics, Inc., Substantially All of the Assets
Bankruptcy
May 1, 2016
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact DNIB Unwind, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.